CINECA IRIS Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi di Torino.
AperTO è l'archivio istituzionale Open Access destinato a raccogliere, rendere visibile e conservare la produzione scientifica dell'Università degli Studi di Torino.
EnglishCHIARLE, Roberto
Risultati 1 - 20 di 146 (tempo di esecuzione: 0.0 secondi).
| Titolo | Data di pubblicazione | Autore(i) | |
|---|---|---|---|
| 1 | α-enolase, a SERPA-defined antigen elicits both CD4 and CD8 T cell reactivity | 2005 | Tomaino B; Ciccarelli M; Ponzetto A; Alessio M; Chiarle R.; Giovarelli M.; Novelli F. |
| 2 | Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma | 2019 | Menotti, Matteo; Ambrogio, Chiara; Cheong, Taek-Chin; Pighi, Chiara; Mota, Ines; Cassel, Seth H.; Compagno, Mara; Wang, Qi; Dall’Olio, Riccardo; Minero, Valerio G.; Poggio, Teresa; Sharma, Geeta Geeta; Patrucco, Enrico; Mastini, Cristina; Choudhari, Ramesh; Pich, Achille; Zamo, Alberto; Piva, Roberto; Giliani, Silvia; Mologni, Luca; Collings, Clayton K.; Kadoch, Cigall; Gambacorti-Passerini, Carlo; Notarangelo, Luigi D.; Anton, Ines M.; Voena, Claudia*; Chiarle, Roberto |
| 3 | Vaccination with ENO1 DNA Prolongs Survival of Genetically Engineered Mice with Pancreatic Cancer. | 2013 | Cappello P; Rolla S; Chiarle R; Principe M; Cavallo F; Perconti G; Feo S; Giovarelli M; Novelli F. |
| 4 | The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration | 2007 | VOENA C; CONTE C; AMBROGIO C; BOERI ERBA E; BOCCALATTE F; MOHAMMED S; JENSEN ON; PALESTRO G; INGHIRAMI G; CHIARLE R |
| 5 | Type B1 thymoma | 2004 | G. PALESTRO; R. CHIARLE; A. MARX; H.K. MULLER-HERMELINK; I. SNG |
| 6 | Tumor resistance against ALK targeted therapy-Where it comes from and where it goes | 2018 | Sharma G.G.; Mota I.; Mologni L.; Patrucco E.; Gambacorti-Passerini C.; Chiarle R. |
| 7 | Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: A tissue micro array-based multicenter study. | 2014 | Lattanzio R;La Sorda R;Facciolo F;Sioletic S;Lauriola L;Martucci R;Gallo E;Palmieri G;Evoli A;Alessandrini G;Ruco L;Rendina EA;Truini M;Chiarle R;Barreca A;Pich A;Ascani S;Remotti D;Tunesi G;Granone P;Ratto GB;Puma F;Pescarmona E;Piantelli M;Marino M;Carlini S;Cerasoli V;Corzani F;Melis E;Filippetti M;Canalini P;Palestro G;Lalle M;Ruffini E;Ceribelli A;Rinaldi M;Thymic Epithelial Tumor Working Group |
| 8 | A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment | 2015 | Alberti, Diego; Protti, Nicoletta; Toppino, Antonio; Deagostino, Annamaria; Lanzardo, Stefania; Bortolussi, Silva; Altieri, Saverio; Voena, Claudia; Chiarle, Roberto; Geninatti Crich, Simonetta; Aime, Silvio |
| 9 | The STAT3 isoforms alpha and beta have unique and specific functions | 2004 | MARITANO D; SUGRUE ML; TINININI S; DEWILDE S; STROBL B; FU X; MURRAY-TAIT V; CHIARLE R; POLI V. |
| 10 | The role of mechanistic factors in promoting chromosomal translocations found in lymphoid and other cancers. | 2010 | Zhang Y; Gostissa M; Hildebrand DG; Becker MS; Boboila C; Chiarle R; Lewis S; Alt FW. |
| 11 | The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. | 2011 | Martinelli P; Bonetti P; Sironi C; Pruneri G; Fumagalli C; Raviele PR; Volorio S; Pileri S; Chiarle R; McDuff FK; Tusi BK; Turner SD; Inghirami G; Pelicci PG; Colombo E |
| 12 | The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL | 2009 | Boccalatte FE; Voena C; Riganti C; Bosia A; D'Amico L; Riera L; Cheng M; Ruggeri B; Jensen ON; Goss VL; Lee K; Nardone J; Rush J; Polakiewicz RD; Comb MJ; Chiarle R; Inghirami G |
| 13 | The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinase | 2007 | BERTO G; CAMERA P; FUSCO C; IMARISIO S; AMBROGIO C; CHIARLE R; SILENGO L; DI CUNTO F |
| 14 | The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. | 2001 | CHIARLE R; PAGANO M; G. INGHIRAMI |
| 15 | The battle against ALK resistance: successes and setbacks. | 2012 | Voena C; Chiarle R. |
| 16 | The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination | 2008 | Chiarle R; Martinengo C; Mastini C; Ambrogio C; D’Escamard V; Forni G; Inghirami G |
| 17 | The anaplastic lymphoma kinase in the pathogenesis of cancer | 2008 | R. CHIARLE; C. VOENA; C. AMBROGIO; R. PIVA; G. INGHIRAMI |
| 18 | The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation | 2008 | Ambrogio C; Voena C; Manazza AD; Martinengo C; Costa C; Kirchhausen T; Hirsch E; Inghirami G; Chiarle R. |
| 19 | The Tyrosine Phosphatase SHP2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration. | 2006 | Voena C; Conte C; Ambrogio C; Boeri Erba E; Boccalatte F; Mohammed S; Jensen ON; Inghirami G; Chiarle R. |
| 20 | Targeting oncogenic ALK by stable small interfering RNA induces cell death of human Anaplastic Large Cell Lymphoma cells | 2004 | R Piva; A Manazza; R Taulli; C Ponzetto; R Chiarle; G Inghirami |
Nome completo:
CHIARLE, Roberto
Copyright © 2019